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Abstract
17-estradiol (E2) exerts complex and context-dependent effects in pulmonary hypertension. In hypoxia-induced pulmonary hyper-
tension (HPH), E2 attenuates lung vascular remodeling through estrogen receptor (ER)-dependent effects; however, ER target genes
in the hypoxic lung remain unknown. In order to identify the genome regulated by the E2-ER axis in the hypoxic lung, we performed
a microarray analysis in lungs from HPH rats treated with E2 (75mcg/kg/day)  ER-antagonist ICI182,780 (3mg/kg/day). Untreated
HPH rats and normoxic rats served as controls. Using a false discovery rate of 10%, we identified a significantly differentially regulated
genome in E2-treated versus untreated hypoxia rats. Genes most upregulated by E2 encoded matrix metalloproteinase 8,
S100 calcium binding protein A8, and IgA Fc receptor; genes most downregulated by E2 encoded olfactory receptor 63, secreted
frizzled-related protein 2, and thrombospondin 2. Several genes affected by E2 changed in the opposite direction after ICI182,780 co-
treatment, indicating an ER-regulated genome in HPH lungs. The bone morphogenetic protein antagonist Grem1 (gremlin 1) was
upregulated by hypoxia, but found to be among the most downregulated genes after E2 treatment. Gremlin 1 protein was reduced in
E2-treated versus untreated hypoxic animals, and ER-blockade abolished the inhibitory effect of E2 on Grem1 mRNA and protein. In
conclusion, E2 ER-dependently regulates several genes involved in proliferative and inflammatory processes during hypoxia. Gremlin 1
is a novel target of the E2-ER axis in HPH. Understanding the mechanisms of E2 gene regulation in HPH may allow for selectively
harnessing beneficial transcriptional activities of E2 for therapeutic purposes.
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Introduction
Pulmonary arterial hypertension (PAH) is a progressive
and devastating disease characterized by muscularization,
dysregulated vasoconstriction, and formation of occlusive
lesions in the pulmonary arteries.1–3 These changes lead to
increased right ventricular (RV) afterload and, if left
untreated, RV failure and death.1–3 Despite a strong pre-
disposition for female gender with female-to-male ratios
ranging from 1.4–4:1 in modern patient registries,4–11
female patients survive longer than male patients.4,5 This
phenomenon is referred to as the ‘‘estrogen paradox’’ of
PAH.12
This paradox has been attributed to complex and context-
dependent eﬀects of sex hormones, in particular
17-estradiol (E2). While studies suggest E2 may contribute
to PAH pathogenesis in the setting of altered serotonin or
bone morphogenetic protein receptor 2 (BMPR2) signal-
ing,13–17 we and others showed that E2 is protective during
hypoxia.18–23 Speciﬁcally, we showed that E2 attenuates pul-
monary artery (PA) vasomotor and proliferative responses
to hypoxia.19,20,24 Since no anti-proliferative E2 eﬀects were
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observed in the setting of normoxia, these data suggest that
E2 exerts speciﬁc vasculoprotective eﬀects during hypoxia.
This is clinically relevant, as hypoxia is one of the most
common inducers of pulmonary hypertension (PH) world-
wide.25–27 A better understanding of the pulmonary vascular
targets and the molecular signature of E2 in the hypoxic lung
may allow for identiﬁcation of novel therapeutic targets that
may beneﬁt the millions of patients with hypoxia-induced
PH (HPH). In addition, even though PAH is phenotypically
distinct from HPH, there is overlap in pathophysiological
pathways, and ﬁndings obtained in HPH may help resolve
the estrogen paradox in patients with PAH.
Our previous studies demonstrated that E2 exerts its
hypoxia-speciﬁc anti-proliferative eﬀects in an estrogen
receptor (ER)-dependent manner.20 While we identiﬁed the
pro-proliferative mediator ERK1/2, the cell-cycle inhibitor
p27Kip1 and the autophagy marker LC3B as targets of E2
and the ER in the hypoxic lung and in hypoxic PA endo-
thelial cells (PAECs),20 we hypothesized that E2 has add-
itional targets in the hypoxic lung that have not yet been
identiﬁed and that may be therapeutically targetable.
Speciﬁcally, we hypothesized that E2 in the setting of
chronic hypoxia and through ER-dependent mechanisms
drives a regulatory network distinct from chronic hypoxia
alone, thus allowing for E2 to exert protective eﬀects. Using
microarray analyses of lung tissues from chronically hypoxic
rats treated with E2 alone or with E2 plus the ER antagonist
ICI 182,780 (fulvestrant), we identiﬁed a distinct set of lung
target genes that were modulated by E2 and that were less
robustly aﬀected after co-treatment with ER antagonist. This
ER-dependent genome includes a large list of regulators of
cellular proliferation, signaling, and inﬂammatory responses.
One of the most robustly aﬀected targets was the hypoxia-
inducible protein gremlin 1, a known bone morphogenetic
protein (BMP) signaling inhibitor and mediator of PA cell
proliferation.28 Furthermore, gremlin 1 expression was tran-
scriptionally and translationally repressed by E2 in an ER-
dependent fashion. Taken together, these data suggest that
E2, in an ER-dependent fashion, attenuates hypoxia-inducible
pro-proliferative and pro-inﬂammatory signaling pathways.
Materials and methods
Animal care
All rats used in studies were approved by the Indiana
University School of Medicine Institutional Animal Care
and Use Committee and were adherent with the National
Institutes of Health guidelines for care and use of laboratory
animals under the animal welfare assurance act. Rats had ad
libitum access to food and water.
Experimental model of PH
A group of four male Sprague-Dawley rats (250–300 g,
Charles River, Wilmington, MA, USA) were implanted
with subcutaneous osmotic pumps (Alzet, Cupertino, CA,
USA) containing E2 released at a ﬂow rate of 75 mg/kg/day
for three weeks. This dose results in E2 levels equivalent to
physiological concentrations in adult female Sprague-
Dawley rats.18 An additional group of four male rats were
implanted with E2 osmotic pumps and concomitantly
administered the non-selective ER-antagonist ICI 182,780
(ICI; Tocris, Bristol, UK) daily via subcutaneous injection
(3mg/kg/day). Following one week of recovery, E2,
E2þ ICI treated rats, and four male hypoxic control rats
were exposed to two weeks of hypobaric hypoxia
(Patm¼ 362mmHg; equivalent to 10% FiO2 at sea level) as
described previously20 (Supplemental Fig. 1). An additional
four male rats were used as normoxic controls. All animals
were part of a larger study in which we demonstrated that
E2 ER-dependently attenuates HPH.20 Hemodynamic,
structural, and biochemical characteristics of the experimen-
tal groups were described previously.20 Four animals from
each group were randomly selected for microarray studies.
Vehicle controls for E2 and ICI were tested in prior studies
and found not to have any eﬀects on cardiopulmonary par-
ameters20 (and were therefore not included in the current
analysis).
Tissue processing
Immediately after hemodynamic assessment, animals were
sacriﬁced via exsanguination under isoﬂurane anesthesia.
The lung vasculature was cleared of blood by inserting a
catheter into the PA and ﬂushing it with saline. The left
lung was inﬂated with 1% agarose, ﬁxed for 48 h in 10%
formalin, and used in subsequent immunohistochemical
analysis. The right lung was snap frozen in liquid nitrogen
and used for RNA isolation and western blot analysis.
RV hypertrophy
RV hypertrophy was determined by measuring the weights
of the RV and left ventricle plus septum (LVþS) and cal-
culating the Fulton index (RV/[LVþ S]) as described
previously.20
RNA isolation and microarray analysis
RNA was isolated from lung homogenates using the TRIzol
Plus RNA isolation kit (Ambion, Carlsbad, CA, USA) and
further puriﬁed for microarray analysis using RNeasy clean
up columns (RNeasy mini kit, Qiagen, Germantown, MD,
USA). Quality of the total RNA was assessed by Agilent
Bioanalyzer. The RNA integrity number (RIN) for all sam-
ples was 9. Individual rat lung RNA samples (n¼ 4 per
group) were labeled using the Ambion WT expression kit
(Ambion, Carlsbad, CA, USA) and Aﬀymetrix GeneChip
WT terminal labeling kits (Aﬀymetrix, Santa Clara, CA,
USA) using 100 ng of total RNA for each sample. Each
sample was hybridized individually to Aﬀymetrix Rat
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Gene 1.0 ST arrays followed by data analysis. Chips were
examined for defects and none were found.
CEL ﬁles were imported into Partek Genomics Suite
(Partek, Inc., St. Louis, MO, USA). RMA (robust multi-
array average) signals were generated for the core probe sets
using the RMA background correction, quantile normaliza-
tion, and summarization by Median Polish.29 Summarized sig-
nals for each probe set were log2 transformed. These
log-transformed signals were used for principal component
analysis, hierarchical clustering, and signal histograms to
determine if there were any outlier arrays, and no outliers
were detected. Untransformed RMA signals were used for
fold change calculations. Data were analyzed using a one-
way ANOVA followed by contrasts. Fold changes were calcu-
lated using the untransformed RMA signals. Probe sets with
log2 expression levels <4.0 are very close to background.
Probe sets with average expression levels<4.0 for all treatment
groups were removed before the false discovery rate (FDR)
was calculated using the Storey method.30 Ingenuity pathways
analysis (Qiagen, Germantown, MD, USA) was used to iden-
tify diﬀerentially expressed gene clusters, biological pathways,
and networks. FDR was set at 10%. The microarray data
were deposited in the NCBI Gene Expression Omnibus
(GEO) database (GEO accession number GSE85618).
Quantitative real-time reverse transcription polymerase
chain reaction
Total RNA from 10–30mg snap-frozen lung tissue was
extracted using the RNeasy Fibrous Tissue kit (Qiagen,
Germantown, MD, USA) and quantiﬁed with a
NanoDrop 2000 Spectrophotometer (Thermo Fisher
Scientiﬁc, Waltham, MA, USA). To generate cDNA for
real-time reverse transcription polymerase chain reaction
(RT-PCR) analysis, 1 mg total RNA was reverse transcribed
using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA,
USA). Real-time RT-PCRs were performed using the
Applied Biosystems 7500 Real-time PCR system (Applied
Biosystems, Thermo Fisher Scientiﬁc, Foster City, CA,
USA). TaqMan gene expression assay primers that crossed
exon boundaries were selected to avoid contamination of
genomic DNA (Supplemental Table 1). Changes in
mRNA expression were determined by the comparative
CT (2–CT) method.
31 Hypoxanthine phosphoribosyltrans-
ferase 1 (Hprt1) was used as endogenous control32 and data
were expressed as fold change to normoxic controls.
Western blotting
Lung tissue was homogenized using an Omni international
tissue grinder (Thermo Fisher Scientiﬁc, Waltham, MA,
USA) in ice-cold RIPA lysis buﬀer (Pierce-Thermo Fisher
Scientiﬁc, Waltham, MA, USA) containing proteinase
inhibitor cocktail (EMD-Millipore-Sigma Aldrich,
St. Louis, MO, USA) and PhosStop inhibitor cocktails
(Roche, Pleasanton, CA, USA). After homogenization,
lysate was sonicated for ten 1-s pulses at 100% power and
then centrifuged. The supernatant was saved and used as
whole lung lysate. Protein concentration was measured
using BCA Protein Assay (Pierce-ThermoFisher Scientiﬁc,
Waltham, MA, USA). Rabbit polyclonal anti-Gremlin
(LifeSpan Biosciences, Seattle, WA, USA), anti-phospho-
Smad 1/5/8 (Cell Signaling, Danvers, MA, USA), anti-total
Smad1 (Invitrogen-ThermoFisher Scientiﬁc, Carlsbad, CA,
USA), and anti-BMP2 (Abcam, Cambridge, MA, USA) pri-
mary antibodies were used at a dilution of 1:1000 and mouse
monoclonal anti-BMPR2 (BD Biosciences, San Jose, CA,
USA) and anti-Vinculin (CalBiochem-EMD Millipore,
Temecula, CA, USA) were used at a dilution of 1:1000 and
1:5000, respectively, all in 5% BSA (EMD-Millipore-Sigma
Aldrich, St. Louis, MO, USA) in TBST (25mM Tris, 1M
NaCl, 1% Tween 20). Rabbit-HRP (Cell Signaling,
Danvers, MA, USA) and Mouse-HRP (KPL,
Gaithersburg, MD, USA) secondary antibodies were diluted
1:2000 in 5%non-fat drymilk in TBST.Western blotting was
performed in the lungs of the 16 animals used for microarray
studies with validation of results in lungs from an additional
16 animals (n¼ 4/group) from Lahm et al.20
Immunohistochemistry
Immunoperoxidase staining for gremlin 1 was performed on
formalin-ﬁxed, paraﬃn-embedded lung sections. Sections
were heated in a vegetable steamer for 25 min in citrate anti-
gen retrieval buﬀer (10mM Sodium Citrate, 0.05% Tween-
20, pH 6.0). Goat polyclonal anti-Gremlin (R&D Systems,
Minneapolis, MN, USA) was used at a dilution of 1:100 in
Dako Antibody diluent (Dako-Agilent Technologies,
Carpinteria, CA, USA) and detected with ABC ampliﬁcation
using Universal Vectastain ABC kit (Vector Laboratories,
Burlingame, CA, USA). Analysis was limited to
PAs< 200 mm in diameter. Forty arteries were analyzed per
animal. PAECs were semi-quantitatively assessed for gremlin
staining intensity (0¼ no staining, 1¼weak staining,
2¼moderate staining, 3¼ strong staining, 4¼ extremely
strong staining) by two blinded investigators.
Statistical analysis
Results were expressed as means SEM. Statistical analyses
were performed using one-way ANOVA with multiple com-
parisons between groups with post-hoc Tukey’s comparison
test correction for individual comparisons using Graphpad
Prism 5 software version 5.04. Signiﬁcance was accepted if
P< 0.05.
Results
E2 attenuates HPH in an ER-dependent fashion
The eﬀects of E2 on endpoints of hypoxic pulmonary
hypertension were characterized previously.20 Brieﬂy,
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E2-attenuated hypoxia-induced increases in RV systolic pres-
sure, RV hypertrophy, and pulmonary vascular remodeling.20
These eﬀects were abolished after co-treatment with ER
antagonist. Speciﬁc RV hypertrophy data for the 16 animals
used in the present study are shown in Fig. 1. As shown
before, E2-attenuated hypoxia-induced increases in RV
hypertrophy, and this eﬀect was blocked by co-treatment
with ICI.
E2 regulates a distinct set of ER-dependent genes in HPH
to induce a pattern that is similar to normoxia
Using microarray analysis with an FDR cutoﬀ of 10%, we
identiﬁed 2889 genes that were diﬀerentially regulated across
all four groups. Additionally, 2238 genes were diﬀerentially
expressed in hypoxic animals compared with normoxic con-
trols (Supplemental Table 2). This is in contrast to 1449
genes that were diﬀerentially expressed in hypoxiaþE2 ani-
mals compared with normoxia. Interestingly, 203 genes were
diﬀerentially expressed in hypoxiaþE2 rat lungs compared
with hypoxia alone and 142 genes were diﬀerentially
expressed between hypoxiaþE2 versus hypoxiaþE2þ ICI
(Supplemental Table 2). Heat map analysis of the top 100
genes that were the most diﬀerentially regulated across all
groups revealed that the hypoxiaþE2 group exhibited less
pronounced hypoxia-induced gene upregulation than the
hypoxia or hypoxiaþE2þ ICI groups, resulting in a dis-
tinct expression pattern regulated by E2 that was in part
similar to the pattern seen in normoxia controls (Fig. 2).
Speciﬁc genes identiﬁed in that group are listed in Fig. 3.
While several genes did not reach the threshold of a
1.5-fold change, four genes (thrombospondin 2, Thbs2;
carboxypeptidase X (M14 family) member 2, Cpxm2; Ly6/
Plaur domain containing 1, Lypd1; Gremlin1, Grem1) were
decreased by E2 beyond that threshold. Using Ingenuity
network analysis, the genes most aﬀected by E2 were iden-
tiﬁed to regulate cell movement, immune cell traﬃcking, cell
death and proliferation, protein synthesis, cell-to-cell signal-
ing and interaction, and carbohydrate metabolism (Table 1).
Identification of E2 target genes
We next set out to identify genes most downregulated by
hypoxiaþE2 versus hypoxia alone (Table 2). Genes were
considered signiﬁcantly regulated by E2 if they had fold
change greater than 1.5 in expression versus hypoxia and
an FDR< 0.1. The ﬁve most downregulated genes included
olfactory receptor 63, Olr63 (–2.7-fold versus hypoxia,
Fig. 3a), secreted frizzled-related protein 2, Sfrp2 (–2.63-
fold versus hypoxia, Fig. 3b), Grem1 (–2.16-fold versus hyp-
oxia, Fig. 3c), Thbs2 (–1.99-fold versus hypoxia, Fig. 3d),
and hairy/enhancer-of-split related with YRPW motif 2,
Hey2 (–1.98-fold versus hypoxia, Fig. 3e). These genes are
known to modulate a variety of cell signaling responses,
ranging from G-protein signaling,33 ﬁbrosis and angiogen-
esis,34,35 and cell movement36–38 to cell diﬀerentiation,39,40
making them potentially relevant for HPH pathogenesis.
In contrast to just three downregulated genes with a fold
change >2 and 23 genes with a fold change >1.5, we identi-
ﬁed 23 upregulated genes in hypoxiaþE2 versus hypoxia
animals with a fold change >2, and 70 genes with a fold
change >1.5. Among the most upregulated genes (Table 2),
we identiﬁed matrix metalloproteinase 8, Mmp8 (3.85-fold
change versus hypoxia, Fig. 3f), S100 calcium binding pro-
tein A8, S100a8 (3.35-fold change versus hypoxia, Fig. 3g),
IgA Fc receptor, Fcar (3.53-fold change versus hypoxia,
Fig. 3h), FK506 binding protein 5, Fkbp5 (2.39-fold
change versus hypoxia, Fig. 3i), and cytochrome P450,
family 1, subfamily a, polypeptide 1, Cyp1a1 (2.28-fold
change versus hypoxia, Fig. 3j) as well as resistin-like
gamma, Retnlg (3.33-fold change versus hypoxia), S100 cal-
cium binding protein A9, S100a9 (3.05-fold change versus
hypoxia), roundabout 1, Robo1 (2.80-fold change versus
hypoxia), chemokine (C-X-C motif) receptor 2, Cxcr2
(2.80-fold change versus hypoxia), C-type lectin domain
family 4, member D, Clec4d (2.74-fold change versus hyp-
oxia), period 1, Per1 (2.48-fold change versus hypoxia), and
colony stimulating factor 3 receptor (granulocyte), Csf3r
(2.41-fold change versus hypoxia). Interestingly, these
genes play diverse roles in processes involved in HPH devel-
opment such as cell movement,41,42 antigen presentation,43
inﬂammation,44–46 angiogenesis,47 chemokine signaling,48
cellular growth,49 and estrogen metabolism,50 suggesting
that E2 may exert its eﬀects in HPH in part by targeting
these processes.
Importantly, E2’s eﬀects on several of these genes (Olr63,
Srfp2, Grem1, Thbs2, Mmp8, S100a8, Fkbp5, and Cyp1a1)
were abolished after co-treatment with ICI, suggesting that
Fig. 1. E2 decreases hypoxia-induced RV hypertrophy. Effects of E2 or
ER antagonist ICI 182,780 on RV mass expressed as Fulton’s index (RV
weight divided by left ventricleþ septum weight; RV/[LVþ S], all in
grams). n¼ 4 per group. *P< 0.05 vs. normoxia control, #P< 0.05 vs.
hypoxia, $P< 0.05 vs. hypoxiaþ E2þ ICI. One-way ANOVA with
Tukey’s post-hoc correction. Data expressed as means SEM.
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Fig. 2. Heat map representing 100 most differentially expressed genes between experimental groups. Each row represents an animal sample and
each column represents a gene. Red represents upregulated genes, blue represents downregulated genes. Hierarchal clustering analysis indicates
hypoxia and hypoxiaþ E2þ ICI exhibit the most similarities, while hypoxiaþ E2 exhibits the closest similarity to normoxic controls. Note that a
subset of genes in the hypoxiaþ E2 group demonstrated an expression pattern similar to that in normoxia controls (black box), whereas no such
pattern was noted in hypoxia controls or hypoxic animals treated with E2 and ER antagonist ICI 182,780. Nkd2, naked cuticle homolog 2
(Drosophila); Thbs2, thrombospondin 2; Cpxm2, carboxypeptidase X (M14 family), member 2; Olfml2b, olfactomedin-like 2B; Lypd1, Ly6/Plaur
domain containing 1; Uck2, uridine-cytidine kinase 2; Mustn1, musculoskeletal, embryonic nuclear protein 1; Inhba, inhibin beta-A; Rab4a, RAB4A,
member RAS oncogene family; Fbln7, fibulin 7; Grem1, gremlin 1; Ccl21, chemokine (C-C motif) ligand 21; Fblim1, filamin binding LIM protein 1;
Dpys15, dihydropyrimidinase-like 5; Robo4, roundabout homolog 4.
Fig. 3. E2 treatment attenuates hypoxia-induced changes in gene expression patterns in an estrogen receptor-dependent manner. Several genes
were identified that after E2 treatment changed in an opposite direction than with hypoxia alone, and in which the effect of E2 was attenuated
after ICI 182,780 co-treatment. (a–e) Genes upregulated in hypoxia (H) vs. normoxia (N) and in hypoxiaþ E2þ ICI 182,780 (Hþ E2þ ICI) vs.
hypoxiaþ E2 (Hþ E2), respectively, and downregulated in hypoxiaþ E2 vs. hypoxia. (a) Olr63, olfactory receptor 63; (b) Sfrp2, secreted frizzled-
related protein 2; (c) Grem1, gremlin 1; (d) Thbs2, thrombospondin 2; (e) Hey2, hairy/enhancer-of-split related with YRPW motif 2. (f–j) Genes
downregulated in hypoxia vs. normoxia and in hypoxiaþ E2þ ICI vs. hypoxiaþ E2, respectively, and upregulated in hypoxiaþ E2 vs. hypoxia.
(f) Mmp8, matrix metallopeptidase 8; (g) S100a8, S100 calcium binding protein A8; (h) Fcar, IgA Fc receptor; (i) Fk5bp, FK506 binding protein 5;
(j) Cyp1a1, cytochrome P450, family 1, subfamily a, polypeptide 1. Genes were considered differentially regulated if fold change was >1.5, with a
group FDR< 0.1, as determined by one-way ANOVA.
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E2 regulates its target genome at least in part via an ER-
dependent mechanism. These ER-regulated genes are
depicted in Fig. 3.
Lastly, we evaluated the eﬀect of hypoxia, hypoxiaþE2,
or hypoxiaþE2þ ICI on gene expression of the two ERs,
Esr1 (encoding ER) and Esr2 (encoding ER). Microarray
analysis revealed that neither Esr1 nor Esr2 expression were
signiﬁcantly aﬀected by any experimental group in our study
compared with normoxic controls (Supplemental Table 3).
Quantitative real-timeRT-PCR validation of E2
target genes
We next validated our microarray ﬁndings by quantitative
real-time RT-PCR. We found that Olr63, Sfrp2, Grem1,
Thsp2, and Hey2 were signiﬁcantly downregulated in E2
treated versus untreated hypoxic lungs (Fig. 4a–e). The
repression of Olr63 and Hey2 by E2 was blocked after inhib-
ition of estrogen receptors by ICI. ICI tended to upregulate
Sfrp2, Grem1, and Thbs2, but these eﬀects were less robust
and not statistically diﬀerent versus E2. Additionally, we
found Mmp8, Fcar, S100a8, and Fkbp5 to be signiﬁcantly
upregulated in hypoxiaþE2 animal lungs compared with
hypoxia alone, while E2-mediated upregulation of these
genes was blunted after ICI treatment (Fig. 4f–i).
Although not signiﬁcant, E2 tended to increase Cyp1a1
compared with hypoxia alone (Fig. 4h). Taken together,
these ﬁndings corroborate our key microarray ﬁndings.
E2 decreases gremlin 1 and phosho-Smad 1/5/8 protein
in HPH rats
Given that Grem1 was among the most downregulated genes
in E2-treated animals, and given the well-established role of
gremlin 1 as an inhibitor of BMP signaling and mediator of
PAH development,28,51 we further investigated E2’s eﬀects
on this peptide. Ingenuity network analysis in hypoxiaþE2
versus hypoxia animals revealed an extensive network of
genes associated with gremlin 1 (Fig. 5). Interestingly, sev-
eral known modulators of PAH development (e.g. Bmp2,
Smad 1/5/8) were included in this network. The ﬁnding
that the gremlin 1 target Bmp2 tended to be upregulated
by E2 (Fig. 5 and Supplemental Fig. 2a; 1.42-fold change
versus hypoxia, P value¼ 0.004, FDR¼ 0.13) and was sig-
niﬁcantly upregulated versus normoxia by RT-PCR
(Supplemental Fig. 2b) was of particular interest, suggesting
that the gremlin-BMP2 axis may be a potentially relevant
target of E2 in HPH rats. To investigate this further, lung
gremlin 1 protein expression was evaluated by immunohis-
tochemistry and western blot. Interestingly, gremlin 1 was
primarily localized to the pulmonary vasculature (Fig. 6a).
Following expression of its gene, gremlin 1 protein was
Table 2. List of genes most regulated during hypoxia by E2.
Gene Fold change P value FDR
Most downregulated genes in hypoxiaþ E2 vs. hypoxia
Olr63 –2.70 0.0007 0.09
Sfrp2 –2.63 0.0005 0.09
Grem1 –2.16 0.00001 0.057
Thbs2 –1.99 0.0002 0.084
Hey2 –1.98 0.0007 0.091
Scara3 –1.90 0.0001 0.078
Fam151a –1.88 0.0005 0.09
Cxcl5 –1.86 0.0006 0.09
Lypd1 –1.78 0.0001 0.07
Meox2 –1.77 0.0009 0.09
Most upregulated genes in hypoxiaþ E2 vs. hypoxia
Mmp8 3.85 0.0004 0.08
Fcar 3.53 0.0004 0.08
S100a8 3.35 0.0001 0.07
Retnlg 3.33 0.0009 0.09
S100a9 3.05 0.0006 0.09
Robo1 2.80 0.00002 0.05
Cxcr2 2.80 0.0009 0.09
Clec4d 2.74 0.0010 0.09
Per1 2.48 0.0012 0.10
Csf3r 2.41 0.0015 0.10
Hypoxiaþ E2 vs. hypoxia genes were considered significantly downregulated if
the difference was greater than –1.5 fold change, P< 0.05, and FDR< 0.1 and
upregulated if difference was greater than 1.5 fold change, P< 0.05, and
FDR< 0.1.
Olr63, olfactory receptor 63; Sfrp2, secreted frizzled-related protein 2; Grem1,
Gremlin 1; Thbs2, Thrombospondin 2; Hey2, hairy/enhancer-of-split related
with YRPW motif 2; Scara3, scavenger receptor class A, member 3;
Fam151a, family with sequence similarity 151, member A; Cxcl5, chemokine
(C-X-C motif) ligand 5; Lypd, Ly6/Plaur domain containing 1; Meox2, mesen-
chyme homeobox 2; Mmp8, matrix metalloproteinase 8; Fcar, IgA Fc receptor;
S100a8, S100 calcium binding protein A8; Retnlg, resistin-like gamma; S100a9,
S100 calcium binding protein A9; Robo1, roundabout guidance receptor 1;
Cxcr2, chemokine (C-X-C motif) receptor 2; Clecd4, C-type lectin domain
family 4, member D; Per1, period homolog 1; Csf3r, colony stimulating factor
3 receptor (granulocyte).
Table 1. Top associated network functions affected in E2-treated
hypoxic animals (vs. untreated hypoxia controls).
Network functions Score*
Cell death, nervous system development and function,
organ morphology
45
Cellular movement, hematological system development and
function, immune cell trafficking
38
Cardiac necrosis/cell death, cell death, cellular growth and
proliferation
35
Protein synthesis, cardiovascular disease, genetic disorder 35
Cell-to-cell signaling and interaction, renal and urological
system development and function, carbohydrate
metabolism
35
*Score determined by number of molecules, cellular, and disease processes
predicted to be affected by differentially regulated genes in hypoxiaþ E2 vs.
hypoxia alone as determined by Ingenuity software.
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decreased in hypoxiaþE2 treated rats versus hypoxia alone
(Fig. 6a and b), whereas ICI co-treatment attenuated this
eﬀect. Analysis of whole lung tissues by western blot con-
ﬁrmed this ﬁnding (Fig. 6c and d), indicating that gremlin 1
indeed is a target of E2 and the ER in HPH.
We next evaluated expression of BMP2’s downstream
targets phospho-Smad 1/5/8 and Id1. E2 ER-dependently
attenuated hypoxia-induced decreases in Smad 1/5/8 phos-
phorylation (Fig. 6c and e), suggesting that ER signaling
may be necessary to maintain lung phospho-Smad 1/5/8
levels. Similarly, Id1 tended to be increased by E2 in hypoxic
animals (P¼ 0.07) and was signiﬁcantly decreased after ICI
co-treatment (Fig. 6c and f). While the BMP2 receptor
Bmpr2 was not signiﬁcantly aﬀected by E2 in our micro-
array (Supplemental Fig. 2a), real-time RT-PCR analysis
identiﬁed Bmpr2 RNA to be signiﬁcantly decreased by hyp-
oxia (Supplemental Fig. 2c), with a trend for increase after
E2 treatment. BMP2 and BMPR2 protein expression were
not signiﬁcantly aﬀected by hypoxia or E2 (Supplemental
Fig. 2d–f). Taken together, these data suggest an ER-
mediated decrease in gremlin 1 expression and BMP down-
stream signaling in chronically hypoxic rat lungs.
Discussion
We report a novel and distinct regulatory network mediated
by E2 under hypoxic conditions that is diﬀerent from hyp-
oxia alone. The regulatory pattern mediated by E2 was
reversed by treatment with ICI, indicating that these genes
are under the transcriptional regulation of the ER. The ER-
dependent E2 target genome encodes proteins that range in
function from modulators of BMP signaling (Grem1), ster-
oid metabolism (Cyp1a1), immune response (Fcar, Thbs2),
calcium signaling (Fkbp5, S100a8), cytoskeletal function
(Olr63), extracellular matrix composition (Mmp8), Notch
signaling (Hey2), and Wnt signaling (Sfrp2; summarized in
Supplemental Fig. 3).
Several of these genes could play a role in HPH develop-
ment. For instance, we identiﬁed gremlin 1 as a novel target
of E2 in the pulmonary vasculature. Gremlin1 is an inhibitor
of BMP 2, 4, and 7 (all of which are highly expressed in the
pulmonary vasculature35) and is increased in PAH
patients.52–54 Increased gremlin 1 expression downregulates
BMP-mediated signaling and increases PA smooth muscle
cell proliferation and PA remodeling.28 Here we show for
the ﬁrst time that gremlin 1 is downregulated by E2 under
hypoxic conditions by an ER-dependent mechanism. Our
studies were not designed to determine if E2 directly or
indirectly regulates gremlin 1 expression, but given the
presence of a putative estrogen response element in the
Grem1 promoter (as reported by SABiosciences’
proprietary DECODE database (http://www.sabiosciences.
com/chipqpcrsearch.php?app¼TFBS), future studies will
investigate if estrogen directly regulates gremlin 1.
Changes in Smad 1/5/8 phosphorylation and Id1 expres-
sion were reciprocal to changes in gremlin 1 abundance.
This suggests that the changes in gremlin 1 had a functional
relevance on BMP signaling and that gremlin 1 may be a
clinically relevant target of E2 in HPH. Interestingly, a
second BMP inhibitor, Bambi, had a similar expression pat-
tern to gremlin 1 (–1.5 fold change hypoxiaþE2 versus hyp-
oxia), although the FDR was above the 0.1 cutoﬀ.
Fig. 4. Quantitative real-time RT-PCR microarray gene validation. Genes identified in the microarray as differentially regulated by hypoxiaþ E2
vs. hypoxia were validated using quantitative real-time RT-PCR. (a–e) Genes downregulated in hypoxiaþ E2 vs. hypoxia. (a) Olr63, olfactory
receptor 63; (b) Sfrp2, secreted frizzled-related protein 2; (c) Grem1, gremlin 1; (d) Thbs2, thrombospondin 2; (e) Hey2, hairy/enhancer-of-split
related with YRPW motif 2. (f–j) Genes upregulated in hypoxiaþ E2 vs. hypoxia. (f) Mmp8, matrix metallopeptidase 8; (g) S100a8, S100 calcium
binding protein A8; (h) Fcar, IgA Fc receptor; (i) Fk5bp, FK506 binding protein 5; (j) Cyp1a1, cytochrome P450, family 1, subfamily a, polypeptide 1.
n¼ 5 per group. *P< 0.05 vs. normoxia control, #P< 0.05 vs. hypoxia, $P< 0.05 vs. hypoxiaþ E2þ ICI. One-way ANOVA with Tukey’s post-hoc
correction. Data expressed as means SEM.
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Fig. 5. Network of genes associated with gremlin 1 in hypoxiaþ E2 vs. hypoxia. Ingenuity network analysis in hypoxic animals treated with E2 (vs.
untreated hypoxic animals) revealed an extensive network of genes associated with gremlin 1 that includes several known modulators of PAH
development (e.g. Bmp2, Smad 1/5/8). Green indicates downregulation, red indicates upregulation. Color intensity is proportional to fold change.
Values under each gene represent P value, FDR, and fold change vs. hypoxia. Relationships between molecules are represented as follows: single
lines¼ binding; line with bar at the end¼ inhibition; line with filled arrowhead¼ activation; line with bar and filled arrowhead¼ activation and
inhibition; line with circular head¼ result of action; line with closed arrowhead¼ translocation; arrow¼ reaction; arrow with diamond¼ enzyme
catalyzed reaction; bold line¼ direct interaction; dotted line¼ indirect interaction. Grem1, gremlin 1; Col8A1; collagen 8A1; KLF9, Kruppel-like
factor 9; Gfra 1, GDNF Family Receptor Alpha 1; Cyp17, Cytochrome P450 17; PMP22, peripheral myelin protein 22; Clec11a, C-Type Lectin
Domain Family 11, Member A; Kdm6b, Lysine (K)-Specific Demethylase 6B; PPm1b, Protein Phosphatase, Mg2þ/Mn2þ Dependent, 1B; Odh22,
octano1 dehydrogenase; Rps6ka5, ribosomal protein S6 kinase A5;Maged1, Melanoma Antigen Family D1; Znf638, Zinc Finger Protein 638; Plscr4,
Phospholipid Scramblase 4; Efemp2, EGF Containing Fibulin-Like Extracellular Matrix Protein 2; Bmp2, Bone morphogenetic protein 2; Rps6ka,
ribosomal protein S6 kinase A; Ciap, Calf Intestinal Alkaline Phosphatase; Htra2, HtrA Serine Peptidase 2; Znf423, Zinc Finger Protein 423; Ebf1,
Early B-Cell Factor 1; Postn, Periostin, Osteoblast Specific Factor; Soat1, Sterol O-Acyltransferase 1; Aldh1a3, Aldehyde Dehydrogenase 1 Family,
Member A3; Nfix, Nuclear Factor I/X (CCAAT-Binding Transcription Factor; Pir, Pirin (Iron-Binding Nuclear Protein); NFkb, NF-kappaB; Snl1, SWI-
independent3; Senp2, Sentrin-specific protease 2; Plk2, Polo-Like Kinase 2; Il17rb, Interleukin-17 receptor B; Hif3a, Hypoxia inducible factor 3
alpha subunit.
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In addition to Grem1, its target Bmp2 tended to be upre-
gulated in lungs of hypoxic animals treated with E2. While
RT-PCR cemented this ﬁnding, western blotting results did
not recapitulate this pattern. Similarly, RT-PCR and western
blotting ﬁndings diﬀered for BMPR2. This discrepancy is not
surprising, since BMPR2, similar to other cell surface recep-
tors, is internalized and degraded upon ligand binding.55–58
This observation would also explain why BMPR2 protein
was not increased by E2. Increased phospho-Smad1/5/8
and target Id1 expression, on the other hand, provides
evidence that BMP signaling is indeed aﬀected by E2.
Besides Grem1, E2 aﬀected expression of several other
genes that may be of relevance to HPH and PAH pathogen-
esis. For example, Cyp1a1, an enzyme which facilitates the
oxidation of E2 into 2-hydroxy- and 4-hydroxy-metabo-
lites,12,59,60 was the most downregulated gene in hypoxia
versus normoxia (–23-fold change versus normoxic controls).
Conversely, hypoxiaþE2 animals exhibited a 2.28-fold
increase in Cyp1a1 gene expression compared with hypoxic
animals. The less reduced expression of Cyp1a1 suggests that
in E2-treated animals there may be an increased conversion
of E2 to its less harmful estrogen hydroxy- and methoxy-
metabolites as opposed to its more harmful metabolite
16-hydroxyestrone, which is not generated through
Cyp1a1.61 Since E2’s hydroxy-metabolites exert their eﬀects
without activating the ER,61,62 this may also explain why not
all of E2’s target genes were aﬀected by ER blockade.
S100a8 and S100a9 (3.35- and 3.05-fold increase in
hypoxiaþE2 versus hypoxia) are known modulators of
inﬂammatory and proliferative responses.45 While little is
known about their role in PAH, a recent study in chronic-
ally hypoxic mice identiﬁed S100a9 as one of the most upre-
gulated genes during re-exposure to room air (when the
pulmonary vascular remodeling process regresses),63 sug-
gesting a potential role as a mediator of reverse pulmonary
remodeling. The E2-related increase in S100a9 and its
dimerization partner S100a8 could therefore be interpreted
as a potential mechanism implicated in mediating E2’s bene-
ﬁcial eﬀects on hypoxia-induced PA remodeling.
Another interesting target of E2 is Hey2 (–1.98 fold
change versus hypoxia). Hey2 is a downstream target of
Notch signaling shown to suppress p27Kip1, a known cell
Fig. 6. Treatment with E2 ER-dependently decreases gremlin 1 protein in hypoxic lungs. Lungs from normoxic control animals, untreated
hypoxic animals, and hypoxic animals treated with E2 with or without concomitant ICI 182,780 treatment were analyzed for gremlin 1 expression.
(a) Representative immunohistochemistry stains demonstrate that gremlin 1 is localized to the pulmonary vasculature (arrows) and that E2
treatment is associated with a decrease in gremlin 1 expression. No such decrease was noted in hypoxic animals treated with E2 in the presence
of estrogen receptor antagonist ICI 182,780. 20 magnification, scale bar¼ 100 mm. (b) Quantification of gremlin 1 stain in the pulmonary
vasculature. (c) Western blot analysis and (d–f) densitometry of gremlin 1 and its downstream targets p-Smad1/5/8 and Id1 in lung homogenates.
(b) n¼ 4/group, (d–f) n¼ 8/group (including the 16 animals used in microarray studies plus 16 additional animals from McMurtry et al.22 used for
validation of results). *P< 0.05 vs. normoxia control, #P< 0.05 vs. hypoxia, $P< 0.05 vs. hypoxiaþ E2þ ICI. One-way ANOVA with Tukey’s post-
hoc correction. Data expressed as means SEM.
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cycle inhibitor.64,65 Interestingly, our previous ﬁndings dem-
onstrate that E2 increases p27Kip1, thus suppressing prolif-
erative processes within the pulmonary vasculature.20 It is
conceivable that this occurs, at least in part, via Hey2
suppression.
Taken together, these ﬁndings suggest that E2 targets
several genes that are established or potential modiﬁers of
vascular homeostasis and HPH and/or PAH development
(Supplemental Fig. 4). However, the role of E2 in the pul-
monary vasculature is complex, and while E2 has been
shown to be vasculoprotective in hypoxia by inducing vaso-
dilation, decreasing remodeling of small pulmonary vessels,
and decreasing PAEC proliferation, it has also been impli-
cated in PAH development in the setting of BMPR2 muta-
tions or abnormalities in serotonin signaling, thus
suggesting context-speciﬁc eﬀects (reviewed in 12). Even in
the setting of hypoxia, we noticed changes in gene patterns
that would be considered unfavorable in individuals with
PH. For example, E2 increased expression of Cxcr2, a
gene encoding a chemokine receptor involved in PH patho-
genesis.66 These data suggest that a better understanding of
E2’s eﬀects in HPH and PAH may allow for dissecting bene-
ﬁcial and detrimental eﬀects in various contexts, thus allow-
ing for targeted and context-dependent manipulation of E2
and ER signaling.
Our studies were performed in male animals and there-
fore do not provide information on the E2-dependent
genome in hypoxic females. Since studies in female animals
are confounded by changes in E2 levels due to the estrous
cycle, such studies would be more diﬃcult to perform and
require a large number of animals. Given this limitation,
these studies are beyond the scope of the current manu-
script, but will be the focus of future investigations. In
addition, our studies do not allow for detection of changes
occurring early in the remodeling process (e.g. within the
ﬁrst few days), which would require time courses and thus
a large number of animals. Finally, the HPH model does
not necessarily recapitulate features of PAH. However,
chronic hypoxia is a major driver of WHO group 3 PH
and thus of importance to a large patient population.26
Additionally, several aspects of HPH (e.g. inﬂammation,
growth factor activation, media hypertrophy25) are also
applicable to PAH. Despite these limitations, our studies
provide several important ﬁndings and are a critical ﬁrst
step in identifying novel targets of E2 and the ER in HPH,
thus providing the rationale and basis for future mechan-
istic evaluations focused on developing novel therapeutic
strategies for HPH.
In summary, we provide the ﬁrst evidence of an ER-
dependent, E2-speciﬁc lung genome in HPH. E2’s target
genes include genes involved in regulating proliferative pro-
cesses, angiogenesis, ECM composition, immune responses,
as well as calcium, Notch/Wnt and BMP signaling, suggest-
ing that E2’s protective eﬀects in HPH may encompass
modulation of these pathways. A better understanding of
the eﬀects of hypoxia and E2 on these processes may help
solve the ‘‘estrogen paradox’’ in PAH and allow for identi-
ﬁcation of novel molecular targets in HPH as well as PAH.
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